Skip to content

Facing up to the challenges in our industry

Home > 2021/2022 Integrated Annual Report > Facing up to the challenges in our industry

2021/2022 Integrated Annual Report

Striving to constantly expand access to health care

Servier took part in Access Accelerated

This global partnership enhances access to non-communicable disease (NCDs) prevention, treatment and care in low- and lower-middle-income countries.

A comprehensive range of health care solutions

Brand-name medicines, generic medicines, and digital health

1,500

A range of over 1,500 generic medicines

501 million

standard boxes of brand-name medicines were produced in 2021/2022

TREND 2

Continuously innovating to serve patient needs

Our answers:

  • Symphogen our center of excellence for high-quality monoclonal and bispecific antibodies ;
  • Cutting-edge expertise in small molecules, antisense oligonucleotides (ASOs) and monoclonal antibodies ;

  • Open innovation driving collective intelligence: the R&D center in Boston and the R&D Institute in Paris-Saclay.

29

Collaborations with 29 international patient organizations in 2021/2022

70

Over 70 scientific partnerships and collaborations around the world with pharmaceutical companies, biotechs, start-ups and academic labs

Read more

TrEND 3

Furthering the efforts of the pharmaceutical industry in quid profonde mutation

Our answers:

  • Continuously adapting our production facilities and supply chain in order to best respond to patient needs ;
  • Significant presence in emerging economies.

More than 9 out of 10 boxes

of Servier brand-name medicines are sold outside France

97%

of the active ingredients used in the Group’s brand-name medicines are produced by Servier in France

TrEND 4

Combating climate change and related risks

Our answers:

  • Biodiversity: In 2021, Servier joined act4nature international, a voluntary commitment to protect biodiversity ;

  • 1 EcoDesign Program to even more effectively integrate social and environmental concerns into the medicine life cycle ;
  • 2023 target 100% of Servier brand-name medicines to be developed in accordance with an ecodesign approach.

25%

Reduction targeted across all our direct and indirect emissions by 2030

-5.2%

Between 2021 and 2022, we reduced the volume of air freight between our production facilities in Loiret (France) and Arklow (Ireland) by 5.2%, switching instead to sea freight

Read more

TrEND 5

Fostering a fulfilling and meaningful working environment for employees

Our answers:

Our employer promise: Why choose us?

  • Do meaningful and purpose-driven work ;
  • Rise to the challenge with us ;
  • Drive one’s own career.

42

HR labels obtained in 2022 including 34 subsidiaries certified Great Place to Work, 1 Happy Trainees and 7 Top Employer

4,23/5

overall engagement score among Servier Group employees in 20221

79 %

of employees would recommend Servier as a great place to work1

Read more

(1) Annual engagement survey conducted with the Gallup Institute – 2022 Group results

Download the 2021/2022 Integrated Annual Report